Genomic analysis reveals low tumor mutation burden which may be associated with GNAQ/11 alteration in a series of primary leptomeningeal melanomas
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd..
Primary central nervous system melanoma is rare and characterized by a variable prognosis, and no current treatment guidelines exist. We describe the clinical course of a 70-year-old female patient diagnosed with primary leptomeningeal melanoma (LMN) whose case represents the diagnostic and management challenges of this tumor. Targeted genomic sequencing of 315 genes from this tumor revealed GNAQ Q209L mutation and low (4 mutations/Megabase) tumor mutation burden (TMB). Wild-type NRAS, KIT, and BRAF were also observed. A cohort of 4,787 melanomas was subsequently analyzed to identify additional primary central nervous system melanomas, of which 10 additional tumors met pathologic criteria (0.21% of total melanoma cohort). These tumors were genomically assessed according to the same targeted sequencing panel, and 6 of the tumors were also found to harbor a GNAQ mutation. All 10 tumors had low (less than or equal to 2 mutations/Megabase) TMB indicating a potential trend between G-protein-coupled receptor (GPCR) alterations and low TMB in LMNs. GPCR alterations were found to significantly correlate with TMB across the cohort of 4,787 melanomas, supporting this potential finding in the limited LMN subset.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Pigment cell & melanoma research - 33(2020), 3 vom: 16. Mai, Seite 458-465 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fortin Ensign, Shannon [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.02.2021 Date Revised 04.02.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/pcmr.12839 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM302682562 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM302682562 | ||
| 003 | DE-627 | ||
| 005 | 20231225111232.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/pcmr.12839 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1008.xml |
| 035 | |a (DE-627)NLM302682562 | ||
| 035 | |a (NLM)31663661 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fortin Ensign, Shannon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Genomic analysis reveals low tumor mutation burden which may be associated with GNAQ/11 alteration in a series of primary leptomeningeal melanomas |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.02.2021 | ||
| 500 | |a Date Revised 04.02.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | ||
| 520 | |a Primary central nervous system melanoma is rare and characterized by a variable prognosis, and no current treatment guidelines exist. We describe the clinical course of a 70-year-old female patient diagnosed with primary leptomeningeal melanoma (LMN) whose case represents the diagnostic and management challenges of this tumor. Targeted genomic sequencing of 315 genes from this tumor revealed GNAQ Q209L mutation and low (4 mutations/Megabase) tumor mutation burden (TMB). Wild-type NRAS, KIT, and BRAF were also observed. A cohort of 4,787 melanomas was subsequently analyzed to identify additional primary central nervous system melanomas, of which 10 additional tumors met pathologic criteria (0.21% of total melanoma cohort). These tumors were genomically assessed according to the same targeted sequencing panel, and 6 of the tumors were also found to harbor a GNAQ mutation. All 10 tumors had low (less than or equal to 2 mutations/Megabase) TMB indicating a potential trend between G-protein-coupled receptor (GPCR) alterations and low TMB in LMNs. GPCR alterations were found to significantly correlate with TMB across the cohort of 4,787 melanomas, supporting this potential finding in the limited LMN subset | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a GNAQ/GNA11 | |
| 650 | 4 | |a central nervous system/leptomeningeal melanoma | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a molecular targeted therapy | |
| 650 | 4 | |a tumor mutation burden | |
| 650 | 7 | |a GNA11 protein, human |2 NLM | |
| 650 | 7 | |a GNAQ protein, human |2 NLM | |
| 650 | 7 | |a GTP-Binding Protein alpha Subunits |2 NLM | |
| 650 | 7 | |a GTP-Binding Protein alpha Subunits, Gq-G11 |2 NLM | |
| 650 | 7 | |a EC 3.6.5.1 |2 NLM | |
| 700 | 1 | |a Bollin, Kathryn |e verfasserin |4 aut | |
| 700 | 1 | |a Millis, Sherri Z |e verfasserin |4 aut | |
| 700 | 1 | |a Hinds, Brian R |e verfasserin |4 aut | |
| 700 | 1 | |a Kosty, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Uchiyama, Christopher |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pigment cell & melanoma research |d 2008 |g 33(2020), 3 vom: 16. Mai, Seite 458-465 |w (DE-627)NLM178364223 |x 1755-148X |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2020 |g number:3 |g day:16 |g month:05 |g pages:458-465 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/pcmr.12839 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2020 |e 3 |b 16 |c 05 |h 458-465 | ||